Please use this identifier to cite or link to this item:
|Title:||Efficacy and safety of anlotinib in patients with advanced colorectal cancer and analysis of prognostic factors|
|Abstract:||Anlotinib, as the new RTK inhibitor molecule, has gained significant interest among researchers in drug development targeting tumors. In this study, we investigated the efficacy and safety of anlotinib in patients with advanced colorectal cancer and analyzed the prognostic factors. A total of 116 patients with advanced colorectal cancer who were treated in the oncology center of our hospital from March 2018 to March 2019 were selected. All patients were divided into a control group and an observation group according to the random number table method, with 58 cases in each group. The patients in the group were given docetaxel treatment, and the observer patients were given anlotinib treatment on this basis. The short-term efficacy, disease control rate, tumor progression time, median survival time and 1-year survival rate of the two groups after treatment were compared; The incidence of adverse reactions during treatment in the two groups; Kaplan-Meier method was used to analyze the prognostic factors of colorectal cancer patients. The total effective rate of patients in the observation group after treatment with anlotinib in the near future was 44.83%, which was significantly higher than 25.86% in the control group, the difference was statistically significant. The disease control rate and 1-year survival rate of the observation group after treatment with anlotinib were significantly higher than the control group, the difference was statistically significant, and the tumor progression time and survival time of the observation group were significantly longer than the control group. There was no significant difference in the total incidence of adverse reactions such as diarrhea, nausea and vomiting, leukopenia, thrombocytopenia, oral mucositis between the two groups of patients during treatment. Kaplan-Meier method analysis found that age, treatment plan, lymph node metastasis, and residual tumor diameter are all risk factors affecting the prognosis of colorectal cancer patients.|
|ISSN:||0975-1009 (Online); 0019-5189 (Print)|
|Appears in Collections:||IJEB Vol.59(10) [October 2021]|
Files in This Item:
|IJEB OCT-21 (BALPEDICON 2021) 59 (10) 740-744 (EB-004) Author copy.pdf||191.09 kB||Adobe PDF||View/Open|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.